TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Personalis ( (PSNL) ).
On November 24, 2025, the Centers for Medicare & Medicaid Services revised its reimbursement rates for Personalis‘ ultrasensitive NeXT Personal® test, which is used for post-treatment cancer recurrence surveillance in stage II and III breast cancer patients. Effective December 1, 2025, the reimbursement rate for the NeXT Personal Dx Breast MRD Recurrence Monitoring Test will be $4,266, and for the NeXT Personal Single Plasma Test, it will be $1,164, impacting the company’s operations by potentially increasing accessibility and utilization of these tests.
The most recent analyst rating on (PSNL) stock is a Hold with a $8.50 price target. To see the full list of analyst forecasts on Personalis stock, see the PSNL Stock Forecast page.
Spark’s Take on PSNL Stock
According to Spark, TipRanks’ AI Analyst, PSNL is a Neutral.
Personalis’ overall stock score reflects significant financial challenges, including declining revenue and negative profitability. Despite positive technical trends and strong clinical adoption, the company’s valuation remains unattractive due to ongoing losses. Strategic partnerships and advancements in reimbursement provide some optimism, but financial stability and growth require substantial improvements.
To see Spark’s full report on PSNL stock, click here.
More about Personalis
Average Trading Volume: 1,252,834
Technical Sentiment Signal: Buy
Current Market Cap: $887.2M
Find detailed analytics on PSNL stock on TipRanks’ Stock Analysis page.